久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

AstraZeneca ups R&D localization

By Zheng Yiran | China Daily | Updated: 2018-12-04 11:00
Share
Share - WeChat
A man walks past an AstraZeneca site in Macclesfield, north England. [Photo/Agencies]

Global biopharmaceutical giant AstraZeneca PLC is promoting the research and development of seven medicines in China, as the company endeavors to strengthen its local R&D capabilities to lower costs for patients.

According to the company, it will take advantage of its production and logistics bases in Wuxi and Taizhou in Jiangsu province to mass produce high-quality and low-cost medicines.

"In addition to the Chinese market, we supply over 70 countries around the world, mainly developing countries. We will use our production advantages to raise production and lower costs, so that patients can benefit from more reasonable prices," said Wang Lei, CEO of AstraZeneca China.

At the China International Import Expo, the Cambridge, United Kingdom-headquartered company demonstrated roughly 30 innovative products that it had brought to China since entering the country 25 years ago. A renal anemia medication, which is being developed locally in China, was displayed at the expo. The drug is set to make its global debut in China next year.

According to Wang, AstraZeneca hopes to bring its global experience to China through the CIIE. The company hopes to integrate its experience with China's successful internet of things ecosystem, colliding with more creative sparks, to meet the country's ever-changing and upgrading medical needs and pain points, by bringing new solutions for Chinese patients, he said.

Wang said China has evolved into the company's second-largest market. As the second-largest medical consumption market in the world, China is also the company's fastest-growing market, with 12 percent year-on-year growth in 2017, he said.

Company statistics show sales revenues stood at $22.5 billion in 2017, of which $2.96 billion was from China, 13.2 percent of the total.

That makes AstraZeneca the second-largest multinational pharmaceutical company in China. To date, it has invested more than $750 million into R&D of medicines that improve people's quality of life

Having operated in China for 25 years, the company continuously adjusts its development strategy, and is beginning to place a heavier emphasis on local R&D innovation.

"In the past, we merely brought foreign drugs into China. From now on, we will develop new drugs locally in China, and bring the products not only to Chinese patients, but also patients from other developing countries. China's innovative drug imports and market access are accelerating. This shifts our emphasis onto specific medicines and anti-cancer drugs," Wang said.

For AstraZeneca, R&D localization is an important opportunity for multinational pharmaceutical companies, leading it to promote the R&D process of seven new drugs in China.

The innovative products and development models based in China can also be applied to other markets, says the company.

"The innovative business model in China will not only stay in China. After being applied to various therapeutic fields, the model can be used in other markets. In the future, governments and medical institutions in other countries will rush to embrace Chinese innovation, and that era is coming soon," Wang said.

Yang Wenya, a medical analyst with Beijing-headquartered think tank EO Intelligence, said: "For medical companies, local innovation in developing new medicines takes advantage of the local production advantages to cut costs and raise efficiency, throughout the process of R&D, production and transportation. In this way, both medical companies and patients benefit. This is an inevitable trend of the international division of labor."

She said China's large patient pool offers abundant resources for clinical research and data is easy to access.

"Producing medicine locally saves the cost of transporting medicines. Also, the two major production logistics bases in Wuxi and Taizhou have obvious agglomeration and scale effects, which can guarantee the quality and quantity of drugs," Yang said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 99久久综合国产精品免费 | 国产美女精品三级在线观看 | 五月色婷婷综合开心网亚 | 尹人香蕉久久99天天拍 | 久久免费大片 | 久久99精品综合国产首页 | 久青草青综合在线视频 | 九草在线观看 | 成年人网站免费在线观看 | 免费黄色网址在线播放 | 国产精品久久久久久影视 | 萌白酱粉嫩jk福利视频在线观看 | 91免费视 | 国产精品美女一区二区 | 日韩国产精品欧美一区二区 | 黄色免费在线网址 | 美国一级片免费看 | 一级毛片在线不卡直接观看 | 欧美xx一片 | 亚洲天堂一区二区 | 国产一区自拍视频 | 国产区久久| 亚洲免费天堂 | 国产成人精品视频免费大全 | 日本美女高清在线观看免费 | 一级特黄爽大片刺激 | 久久综合亚洲一区二区三区 | 久久精品国产亚洲网址 | 91久久网 | 国产成人一区二区在线不卡 | 国产精选在线 | 亚洲成人偷拍 | 亚洲三级在线播放 | 男人的天堂视频在线观看 | 免费一级欧美性大片 | 日本国产在线 | 手机看片欧美 | 免费在线观看亚洲 | 伊人资源| 久草在线免费资源站 | 国产高清精品一区 |